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TMEM70 is involved in the biogenesis of mitochondrial ATP synthase and mutations in the TMEM70 gene impair oxidative
phosphorylation. Herein, we report on pathology and treatment of ATP synthase deficiency in four siblings. A consanguineous
family of Roma (Gipsy) ethnic origin gave birth to 6 children of which 4 were affected presenting with dysmorphic features,
failure to thrive, cardiomyopathy,metabolic crises, and 3-methylglutaconic aciduria as clinical symptoms. Genetic testing revealed a
homozygousmutation (c.317-2A>G) in the TMEM70 gene.While light microscopy was unremarkable, ultrastructural investigation
of muscle tissue revealed accumulation of swollen degenerated mitochondria with lipid crystalloid inclusions, cristae aggregation,
and exocytosis of mitochondrial material. Biochemical analysis of mitochondrial complexes showed an almost complete ATP
synthase deficiency. Despite harbouring the same mutation, the clinical outcome in the four siblings was different. Two children
died within 60 h after birth; the other two had recurrent life-threatening metabolic crises but were successfully managed with
supplementation of anaplerotic amino acids, lipids, and symptomatic treatment during metabolic crisis. In summary, TMEM70
mutations can cause distinct ultrastructural mitochondrial degeneration and almost complete deficiency of ATP synthase but are
still amenable to treatment.
1. Introduction
Skeletal muscle function strongly depends on adenosine tri-
phosphate (ATP) providing energy in most energy con-
suming cellular processes. In mitochondria, aerobic ATP is
generated via oxidative phosphorylation (OXPHOS) com-
prising several respiratory chain subunits of which complexes
I-IV create a proton gradient across the inner mitochondrial
membrane and complex V, also named ATP synthase, trans-
fers protons back to the inner mitochondrial membrane
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[1, 2]. The mitochondrial respiratory chain consists of over
90 mainly nuclear-coded proteins. Complex II of OXPHOS
is the only complex which is exclusively nuclear-coded.
Mitochondrial DNA (mtDNA) consists of 37 genes encoding
13mitochondrial proteins exerting functions in theOXPHOS
system [3]. ATP synthase (complex V) is composed of
two functional domains: F
1
situated in the mitochondrial
matrix and F
0
in the inner mitochondrial membrane [4].
It is assembled of 16 subunits. Two subunits (ATPase 6
and ATPase 8) are encoded by mitochondrial DNA (MT-
ATP6; MT-ATP8); the remaining 14 subunits of complex V
are coded by nuclear DNA. Complex V seems to play an
important role in mitochondria morphology [5]. Although
being rare, there are several complex V related disorders
including mitochondrial and nuclear gene defects. Defects
of nuclear genes resulting in complex V deficiency are
located in ATPAF2, ATP5E, ATP5A1, and TMEM70 genes.
Out of these mutations patients with transmembrane protein
70 (TMEM70) mutations most often present with neonatal
onset of elevated plasma lactate levels, 3-methylglutaconic
aciduria (3-MGA), cardiomyopathy, facial dysmorphism, and
psychomotor and mental retardation [6, 7] and emerged to
be clinically well characterized since the gene description in
2008. The TMEM70 gene on chromosome 8q21.11 contains 3
exons which code for this 21 kD protein, which is probably
located in the inner mitochondrial membrane [8]. The exact
protein function has not yet been determined. At least 65
patients with different genetically confirmedTMEM70muta-
tions were reported to date [9], many from consanguineous
parents of Roma ethnic background [10]. Although genetic
data are available for most patients, ultrastructural examina-
tion of muscle tissue has rarely been performed in patients
with TMEM70 mutations. In one patient with compound
heterozygous mutations (c.117 118dupGT in exon 1 and c.317-
2A>G in intron 2) concentric cristae and reduced OXPHOS
proteins including F1𝛼 as assessed by immunogold labeling
were described [11]; in another patient loss of cristae was
described [12]. Upon transfection of wild type TMEM70 into
patients’ fibroblasts mitochondrial morphology was restored
[5].
Herein, we provide a detailed pathological analysis of
patients with a TMEM70 defect and report on the successful
stabilisation of life-threatening metabolic crises by combined
symptomatic and experimental anaplerotic therapy.
2. Materials and Methods
2.1. Clinical and Epidemiological Data. A consanguineous
couple of Roma background with 2 abortions and 6 living
births was examined (Figure 1(a)). During observation time,
2 of 6 children died. A detailed overview about the clinical
and epidemiological data is provided in Table 1. Parents gave
informed consent for clinical and genetic examination of
their children. Standard laboratory parameters were assessed
according to routine diagnostic protocols.
2.2. Genetic Analyses. Genomic DNA of the affected children
and their family members was studied. Analysis for mtDNA
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Figure 1: Pedigree of family with TMEM70 mutation and genetic
data. (a) Black symbols indicate affected individuals, half-filled sym-
bols indicate heterozygous individuals, and white symbols indicate
phenotypically healthy individuals; circles: female; squares: male;
triangle: miscarriage; crossed symbol: patient deceased; double
lines: consanguineous marriage. The consanguineous parents had
four affected children, two healthy children, and two abortions. The
exact time of the miscarriages is not known (star). The half-filled
individuals have a confirmed homozygous TMEM70 c.317-2A>G
mutation. Sequencing revealed a heterozygous mutation in the
mother and child V ((b), sequencing detail of the heterozygous child
V, arrow indicates site of mutation) and a homozygous mutation in
children I, IV, and VI ((c), sequencing detail of the homozygous
child VI, arrow indicates site of mutation). For the affected and
deceased child II and the phenotypically healthy child III no genetic
information is available.
deletions was performed by standard methods (Long Range-
PCR, Southern Blot analysis). Sanger sequencing of the
TMEM70 gene in children V and VI was performed by
standard methods using the following primer set:
TMEM70-3.1fw 4692 gcactGTATTTATGGTTT-
GATTTTG.
TMEM70-3.1rv 4692 ATGCCGTTTCTCTTCACT-
GG.
Mutation nomenclature referred to NM 017866.5.
2.3. Isolation of Mitochondrial Complexes. Isolation of mito-
chondrial membranes from 15mg skeletal muscle (wet
weight) and solubilization of OXPHOS complexes by dode-
cylmaltoside were performed as described [13]. Protein
complexes were separated by high resolution clear native
electrophoresis (hrCNE) [14] on 4 to 13% acrylamide gradient
gels. An ATP hydrolysis/lead phosphate precipitation assay
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was used to detect ATP synthase. Mitochondrial complexes
were stained by Coomassie Blue G-250 on the same gel. For
separation of individual subunits of protein complexes, native
lanes were separated by two-dimensional sodium dodecyl
sulfate polyacrylamide gel electrophoresis (2D SDS-PAGE)
[15] and stained with silver.
2.4. Histology and Enzyme Histochemistry. Muscle tissue was
obtained by skeletalmuscle biopsies. Snap-frozen tissueswere
stored at −20∘C until use. The specimens were cut at 7 𝜇m
thick slices using a manual cryostat system (Leica CM 1900,
Wetzlar, Germany) and were stained according to standard
protocols including standard myopathological and enzyme
histological stains and finally mounted in Entellan (Merck
Millipore, Darmstadt, Germany). Pathological analysis of the
samples was performed by at least two experienced neu-
ropathologists (DST, MM) using light microscopy (Olympus
BX41, Hamburg, Germany). Due to sending the material to
reference centers, not all slides could be retrieved from our
archive.
2.5. Electron Microscopy. Transmission electron microscopy
(TEM) was used to visualize ultrastructural changes in skele-
tal muscle tissue.Therefore, muscle tissues were initially fixed
overnight using 2.5% glutaraldehyde buffered in cacodylate.
The embedding procedure comprised fixation in 1% osmium
tetroxide, dehydration in a graded ethanol series with an
incubation step with uranyl acetate (between the 50% and
90% ethanol step), and finally rinsing in propylene oxide.The
specimens were then embedded in epoxy resins that poly-
merized for 16 h at 60∘C. After embedding, semithin sections
(0.5 𝜇m) were cut using an ultra-microtome (Leica Ultracut
UCT, Deerfield, IL, USA) with a diamond knife. Sections
were stained with toluidine blue, placed on glass slides, and
examined by light microscopy to select appropriate areas for
ultrathin preparation. Ultrathin sections (50–70 nm) were
cut again using an ultra-microtome. Sections were mounted
on copper grids and contrasted with uranyl acetate for 2-
3 h at 42∘C followed by lead citrate for 20min at room
temperature. Imaging was performed using a FEI Tecnai G2
Spirit Biotwin TEM (Hillsboro, OR, USA) at an operating
voltage of 120 kV. Interpretation of the results was carried out
by two experienced neuropathologists (DST, MM).
3. Results
A family with consanguineous Roma pedigree had 4 clin-
ically affected children, two abortions in the third month
of pregnancy, and two children who were reported to be
healthy (Figure 1). The affected children initially showed
3-MGA with lactate acidosis, left ventricular hypertrophic
cardiomyopathy, and hepatomegaly. The children presented
with failure to thrive and displayed morphological stigmata
including hypertrophic deeply seated ear cartilage and a bird’s
face (Figure 2). Two of the children (children II and VI) died
of cardiac failure and therapy refractory lactic acidosis within
three days after birth. Two affected children (children I and
IV) are long-term survivors with a follow-up of 13 and 7
Table 2: Anaplerotic therapy.
Substance Individual dose and frequency Application
Sodium citrate 3.13% 3 × 500mg × d (∗) p.o. (i.v.)
Glutamine 3 × 500mg × d i.v.
Sodium succinate 3 × 100mg × d i.v.
Sodium aspartate 3 × 100mg × d i.v.
L-Carnitine 3 × 100mg/kg body weight × d p.o.
Coenzyme Q10 3 × 100mg/kg body weight × d p.o.
Vitamin C 1 × 10mg/kg body weight × d p.o.
(∗): dosage control via urine pH; target urine pH should be above pH = 7.
years. Both children showed symptoms of heart failure due
to hypertrophic cardiomyopathy and suffered from recurrent
metabolic crises usually triggered by respiratory or other
infections since birth. Both had significant psychomotor
delays and developed intellectual disability necessitating spe-
cial school enrolment. Among several differential diagnoses
an impaired OXPHOS system due to a mitochondrial disease
was suspected.
Since birth, the children suffered from life-threatening
metabolic crises, whichweremost severe during the postnatal
period but reoccurred later upon situations with elevated
energy demand, for example, infections. In those metabolic
crises the children presented with sucking weakness, vom-
iting, diarrhea, irritability, and in more advanced stages
somnolence and hyperventilation caused by a severe, com-
bined lactic and ketoacidosis. The emergency treatment
aimed to convert catabolism into anabolism and to com-
pensate acidosis. Because of the limitations of glucose as
energy supplement in patients with OXPHOS defects, which
would result in an even more severe acidosis, alternative
energy sources such as amino acids and possibly lipids were
administered. In our patients, the following i.v. regimen
was repeatedly applied with success: glucose (max. 7 g/kg
body weight/day), amino acids (2 g/kg body weight/day),
and lipids (2 g/kg body weight/day). In refractory situations,
a combination of cofactors and essential amino acids was
given including sodium citrate, glutamine, sodium succinate,
sodium aspartate, L-carnitine, coenzyme Q10, and vitamin C
(Table 2). Since the age of six months, child I was supposed
to be on treatment with cofactors to improve cell energy
transfer consisting vitamin E, coenzyme Q10, vitamin C,
lipoic acid, niacin amide, and L-carnitine, but because of poor
compliance child I may not have received the treatment most
of the time.
Biochemical analysis of mitochondrial complexes of
skeletal muscle biopsies from patients II and IV by high
resolution clear native electrophoresis (hrCNE) in-gel ATP
hydrolysis/lead phosphate precipitation assay and Coomassie
stain detected an almost complete ATP synthase deficiency
(Figures 3(a)-3(b)). 2D hrCNE/SDS-gels revealed again dras-
tically reduced amounts of fully assembled ATP synthase
(Figures 3(c)–3(e)). Sanger sequencing of the mtDNA did
not detect any causative mutation. Based on the predominant
cardiac symptomsmutations in a COX assembly factor SCO2
were excluded in child I. In child IV mtDNA deletions and
BioMed Research International 5
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Figure 2: Macroscopic dysmorphic signs in familial TMEM70 mutation. (a, c): child II, one day after birth; (b, d): child IV, at the age of 11
months. Both patients present with prominent dysmorphic ears.
the common mutation m.8993 in MT-ATP6 were excluded.
As complex V deficiency in Roma families had been linked
to TMEM70, initially described by Spiegel et al. [10], Sanger
sequencing of TMEM70 detected the previously reported
mutation c.317-2A>G in a homozygous form in the 3 affected
children (children I, IV, and VI) (Figures 1(b)-1(c)). The
mother and the healthy 5th child were heterozygous. The
father was not willing to be tested, but in this family a paternal
heterozygous mutation of TMEM70 can be assumed.
Light microscopic analysis of standard hematoxylin and
eosin (H and E) stainings and muscle specific enzyme
histochemical stainings (children I, II; IV: data not shown)
showed apart from varying fibres sizes in child II largely
unremarkable myofibres without any specific pathological
findings, especially no ragged-red or cytochrome C oxidase-
(COX-) negative fibres as a hint for a mitochondrial disease
(Figure 4). In contrast, electron microscopy revealed distinct
mitochondrial alterations. In the muscle biopsy of child I
at the age of one year giant mitochondria with abnormal,
sometimes concentric cristae as well as subsarcolemmal
accumulation of swollen mitochondria were present (Figures
5(a)-5(b)). Several mitochondria revealed electron dense
(possibly cristae fragments) and globular inclusions. In child
IV a muscle biopsy was taken on the day of birth, but despite
suboptimal sample quality, electron dense material within
mitochondria and intramitochondrial lipid accumulation
with cristae aggregation were detectable (Figures 5(c)-5(d)).
Electronmicroscopy of child IImuscle biopsy taken at the age
of two days showed accumulation of swollen mitochondria
with abnormal cristae structure as seen in child I but with
an additional separation of the inner and outer membranes
and vacuolation possibly resulting from cristae aggregation
(Figures 5(e)–5(h)). Again subsarcolemmal accumulations
of mitochondria with crystalloid inclusions were present.
Protruding vacuole-like amorphous and electron densemito-
chondrial material from the muscle fibre invoked the term
“exocytosis of mitochondria.”This observation was strength-
ened by the finding of extracellular, membranous structures
with dense globular inclusions which were detached from the
corresponding myofibre (Figure 5(h)).
4. Discussion
The clinical findings together with lactic acidosis and 3-
MGA accumulation during recurrent metabolic crises in
the affected children of the observed family were highly
suggestive of mitochondrial disease [16]. Biochemical anal-
ysis in muscle revealed a reduced or abolished complex V
assembly that was caused by the absence of the protein
complex (Figure 3).Meanwhile, the candidate geneTMEM70
causing a complex V deficiency withmorphological stigmata,
cardiomyopathy, andmetabolic crises frequently occurring in
families of Roma ethnic background had been described [8].
The homozygous TMEM70 (c.317-2A>G) mutation in intron
2 was found in children I, IV, and VI and segregated with the
disease within the family. This mutation has been shown to
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Figure 3: 2D BN-PAGE reveals complex V deficiency. Analysis of muscle tissue in native gels revealing an almost complete deficiency of
the mitochondrial ATP synthase (complex V) (a, b). I-V, mitochondrial complexes I-V; Co., control; 1, child I; 2, child II. (a) Mitochondrial
complexes from homogenized skeletal muscle biopsies were solubilized by dodecylmaltoside, separated by hrCNE, and analyzed by ATP
hydrolysis/lead phosphate precipitation assay. (b) Gel A was restained with Coomassie to display other complexes of the respiratory chain.
Separation of the subunits of mitochondrial complexes by second-dimension SDS-PAGE showed drastically reduced but fully assembled
ATP synthase (complex V) in the patients (c–e). I-V, mitochondrial complexes I-V. Mitochondrial complexes from patient skeletal muscle
were solubilized by dodecylmaltoside and separated by hrCNE. The strip of the native gel was used for 2D SDS-PAGE to resolve the subunit
composition of the mitochondrial complexes, as shown in silver stained gels for (c): control, (D): child I, and (e): child II. Yellow arrows mark
𝛼 and 𝛽 subunits of ATP synthase. Blue arrows indicate the SDHC and SDHD subunits of complex II.
result in aberrant splicing and a loss of the TMEM70 tran-
script [8]. To date, at least 14 additional TMEM70 mutations
have been described leading to a broad clinical spectrum such
as hypospadia [10] or pulmonary arterial hypertension [17], as
summarized in Magner et al. [18].
Two of the four affected children died within 60 hours
postpartum of metabolic crises and heart failure due to
cardiomyopathy refractory to treatment. In all children, the
initial treatment of metabolic crises aimed to stop catabolism
and establish an anabolic metabolism. Therefore energy
supply avoiding an increase of lactate through glucose was
provided with offering alternative substrates for the Krebs
cycle, such as amino acids and fat. In refractory situations,
a mix of cofactors and additional essential amino acids were
added to relieve the metabolic crisis. The concept of supple-
menting essential precursors of the Krebs cycle is referred
to as anaplerotic therapy [19]. An effect of L-carnitine, an
important compound inside the therapy regimen, was shown
in a liver disease mouse model, where mitochondrial abnor-
malities improved upon treatment with L-carnitine [20].
Standardized clinical trials evaluating anaplerotic therapy
are lacking [21], but out of different treatment strategies in
48 patients with TMEM70 deficiency some general recom-
mendations have been deduced by Magner et al. consisting
basically of moderate glucose supplementation, high dose
lipid infusions, and acidosis correction via bicarbonate infu-
sions [18]. The effect of 𝐿-carnitine, coenzyme Q10, and vita-
min C administered here cannot be evaluated exactly; still,
given the few therapeutic options in mitochondrial diseases,
these supplements additionally improved the situation during
metabolic crises in our patients.
In the course of the diagnostic process, muscle biopsies
were taken from three affected children. Light microscopy
analyses did not reveal any major pathological findings
and were especially lacking ragged-red or COX-deficient
fibres that would have been suggestive of a mitochondrial
disease (Figure 3). Interestingly, muscle biopsy from a non-
Roma patient with compound heterozygous TMEM70muta-
tions (c.317-2A>G and c.494G>A, p.Gly165Asp) taken at 30
months of age demonstrated the presence of ragged-red
fibres, which were not present in our patients nor in the other
reported cases with different mutations [22, 23]. It is not clear
by which effects the presence of ragged-red fibres can be
explained in the relatively mildly affected child above.
Additional electron microscopic investigations in our
patients’ muscle tissues (Figure 5) revealed a spectrum from
mild to more severe pathological alterations including giant
mitochondria, subsarcolemmal accumulation of mitochon-
dria, globular inclusions, concentric cristae formation, cristae
fragmentation, and crystalloid inclusions. Child IV showed
most extended morphologic alterations of muscle tissue and
mitochondria and died within 60 hours after birth. Children
I and IV withmilder ultrastructural alterations are long-term
survivors. Prognostic impact of the ultrastructural findings
remains speculative.
Jonckheere et al. reported a fragmented mitochondrial
network and swollen, irregularly shaped mitochondria with
partial to complete loss of the cristae in fibroblasts of a
patient with a deletion of TMEM70 exon 2 (g.2436–3789).
The successful restoration of mitochondrial morphology by
supplement of the wild type TMEM70 vector in patients’
fibroblasts directly links the observed abnormalities to the
defect [5]. In summary, there is much evidence that the
complex V defect resulting from the TMEM70 mutations
directly affects mitochondrial morphology.
Our electron microscopic examination of the muscle
biopsies also showed protrusion of mitochondrial material
at the myofibres’ surfaces as well as circular extracellular
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Figure 4: Light microscopy of patients with TMEM70 mutations. (a, c, e, g): child I, Gomori, ATPase, Oil Red O, and COX; (b, d, f, h):
child II, Gomori, ATPase, Oil Red O, and COX/SDH. Muscle biopsies were snap-frozen and stained according to routine protocols. Apart
from varying fibre size in child II, muscle tissues appear mainly unremarkable. The specimens especially lack typical histological hallmarks
of mitochondriopathies such as ragged-red fibres or COX-deficient fibres.
membranous structures in close vicinity of the myofibres
(Figure 5). Paracrystalline inclusions can be frequently seen
in mitochondrial disorders [24], but perisarcolemmal accu-
mulated mitochondria have not been reported so far in
complex V defects. To date, only single reports about the
so-called “free-floating” mitochondria exist. In Sod1 mutant
micemodelling amyotrophic lateral sclerosis (ALS), extracel-
lular free-floating mitochondria have been described in the
brainstem. They were located extracellularly between capil-
laries and astrocyte processes and accompanied by edema.
In this case the “free-floatingmitochondria” were interpreted
as a result of a blood brain barrier breakdown related to a
basement membrane defect in Sod1 mutant mice [25]. Cells
are believed to have acquired mitochondria from invading
aerobic bacteriamore than a billion years ago employing ATP
as energy source and accepting the bacteria’s residency inside
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Figure 5: Electron microscopy reveals altered mitochondria morphology. Ultrastructural findings in muscle biopsies, child I (a, b), child IV
(c, d), and child II (e–h), magnification as indicated by the scale bar.We detected abnormalmitochondria with concentric cristae (a, cc) as well
as subsarcolemmal (sl) accumulation of swollen mitochondria (m) with crystalline inclusions (ci) in child I (b). In child IV, sample quality
was not optimal; degenerated mitochondria (m) were detected (c, d). In child II (e–h), we detected accumulations of swollen mitochondria
with abnormal cristae structure and separated inner (sim) and outer membrane with vacuoles (v), (g) possibly by intramitochondrial lipid
accumulation with cristae aggregation. Additionally, we saw protrudingmembranes filled with amorphous and electron dense material, most
possibly mitochondria (f, g). Extracellular abnormal membranous structures (m, dense globular inclusion) were detached from the main
myofibre (h).
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the protoeukaryotic cell. This model is referred to as the
“endosymbiotic hypothesis” [26, 27]. Inmitochondriopathies
aggregates of degenerated mitochondria can be observed
frequently subsarcolemmal. Possibly the contractile appara-
tus is less affected if the mitochondria degradation takes
place in a subsarcolemmal position. As a highly speculative
guess, the process of “exocytosis of mitochondria” could be
a way of eliminating mitochondria in a state of extensive
mitochondrial damage as an alternative disposal mechanism.
This might be a reverse step to phylogenetic uptake of mito-
chondria according to the endosymbiotic theory. In yeast,
the phenomenon of mitochondrial regression is connected
to the petit phenotype and can be experimentally induced,
which is then called rho status [28, 29]. Physiologically, the
mitochondrial turnover takes place via mitophagy, the spe-
cific autophagic elimination of mitochondria. If mitophagy
is blocked experimentally, this leads to increased reac-
tive oxygen species (ROS) production and senescence-like
morphology chances including concentric cristae formation
[30, 31]. Important genes related to mitophagy are PINK1
and PARKIN [32], both known to be mutated in familial
forms of Parkinson’s disease. In PINK1 −/− mice changes
in mitochondria size, but not in the overall morphology,
were seen ultrastructurally [33]. Still, the phenomenon of
mitochondrial exocytosis might be a cleaning mechanism of
defect mitochondria; however, further studies are necessary
to decipher the relevance of these observations.
5. Conclusion
In summary, we report on 4 children with TMEM70 defect
from a consanguineous Roma family resulting in complex V
deficiency, 3-MGA, and particular ultrastructural mitochon-
drial alterations. While facing metabolic crises, anaplerotic
therapy was administered attenuating clinical symptoms.
Although clinical studies for anaplerotic therapy in patients
with TMEM70mutations are lacking, we propose anaplerotic
therapy for affected children during metabolic crises as a
promising treatment approach. Our oldest patient with now
14 years of age indicates that long-term survival can be
achieved in TMEM70 patients. This might be important in
genetic counselling of parents with affected children.
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